Slovin, Susan Faith

Publications

Sort by

Co-Author Network

selected publications

Immunotherapy for castration-resistant prostate cancer: has its time arrived?. Expert opinion on biological therapy. 2020 Review GET IT
Times cited: 7
Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?. European urology. 2019 Editorial Article GET IT
Times cited: 2
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 6
Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer. Current treatment options in cardiovascular medicine. 2017 Review GET IT
Times cited: 15
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Review GET IT
Times cited: 25
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal for immunotherapy of cancer. 2016 Academic Article GET IT
Times cited: 71
Immunotherapy for prostate cancer: is prostate an immune responsive tumor?. Current opinion in urology. 2016 Review GET IT
Times cited: 6
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 27
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Conference Paper GET IT
Times cited: 881
Immune Therapy for Prostate Cancer. Cancer journal (Sudbury, Mass.). 2016 Review GET IT
Times cited: 13
Immunotherapy in metastatic prostate cancer. Indian journal of urology : IJU : journal of the Urological Society of India. 2016 Review GET IT
Immunotherapy for genitourinary malignancies in the here and now!. Urologic oncology. 2015 Review GET IT
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. 2015 Academic Article GET IT
Times cited: 24
Biomarkers for immunotherapy in genitourinary malignancies. Urologic oncology. 2015 Review GET IT
Times cited: 13
Metabolism and pharmacokinetics of radium-223 in prostate cancer. Expert opinion on drug metabolism & toxicology. 2015 Review GET IT
Times cited: 5
Immunotherapeutic approaches in prostate cancer: combinations and clinical integration. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Academic Article GET IT
Times cited: 3
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. 2014 GET IT
Times cited: 24
Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. 2014 GET IT
Times cited: 73
American Cancer Society prostate cancer survivorship care guidelines. 2014 GET IT
Times cited: 293
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. International journal of cancer. 2014 Academic Article GET IT
Times cited: 26
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Investigational new drugs. 2014 Academic Article GET IT
Times cited: 74
Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Conference Paper GET IT
Times cited: 84
Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. Immunotherapy. 2013 Review GET IT
Times cited: 4
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 57
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 203
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013 Academic Article GET IT
Times cited: 21
Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. Seminars in oncology. 2013 Review GET IT
Times cited: 13
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2013 Academic Article GET IT
Times cited: 144
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 446
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2012 Academic Article GET IT
Times cited: 57
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 29
Chemotherapy and immunotherapy combination in advanced prostate cancer. Clinical advances in hematology & oncology : H&O. 2012 Review GET IT
Times cited: 27
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study. Cancer. 2012 Academic Article GET IT
Times cited: 65
Are we trumping bone disease in prostate cancer?. Oncology (Williston Park, N.Y.). 2011 Comment GET IT
Times cited: 1
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 28
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 21
Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant. Current drug therapy. 2011 Academic Article GET IT
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 38
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 71
Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 57
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PloS one. 2010 Academic Article GET IT
Times cited: 13
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2010 Academic Article GET IT
Times cited: 171
Seeking informed consent to Phase I cancer clinical trials: identifying oncologists' communication strategies. Psycho-oncology. 2010 Academic Article GET IT
Times cited: 42
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 25
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 80
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. European urology. 2009 Academic Article GET IT
Times cited: 71
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 20
Cancer in older adults: the oncologist's bread and butter. Seminars in oncology. 2008 Editorial Article GET IT
Cognitive effects of hormonal therapy in older adults. Seminars in oncology. 2008 Review GET IT
Times cited: 21
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer research. 2008 Academic Article GET IT
Times cited: 65
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 23
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 125
Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?. Expert review of anticancer therapy. 2008 Review GET IT
Times cited: 3
Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literature. Journal of cutaneous pathology. 2008 Review GET IT
Times cited: 34
Pitfalls or promise in prostate cancer immunotherapy-which is winning?. Cancer journal (Sudbury, Mass.). 2008 Review GET IT
Times cited: 8
Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome. Clinical advances in hematology & oncology : H&O. 2007 Review GET IT
Times cited: 4
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. The Journal of urology. 2007 Academic Article GET IT
Times cited: 36
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. 2007 GET IT
Times cited: 4
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer immunology, immunotherapy : CII. 2007 Academic Article GET IT
Times cited: 65
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 71
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 189
Emerging role of immunotherapy in the management of prostate cancer. Oncology (Williston Park, N.Y.). 2007 Review GET IT
Times cited: 14
Rapid androgen cycling as treatment for patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 22
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. 2006 GET IT
Times cited: 30
Immunologic targeting: how to channel a minimal response for maximal outcome. Current opinion in urology. 2006 Review GET IT
Times cited: 5
Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?. Nature clinical practice. Urology. 2006 Review GET IT
Times cited: 26
Violaceous exanthem as a manifestation of metastatic prostate cancer in skin. 2006 GET IT
Times cited: 2
Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics. 2006 Academic Article GET IT
Times cited: 111
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 80
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 110
Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico. IDrugs : the investigational drugs journal. 2005 Academic Article GET IT
Prostate-specific membrane antigen vaccines: naked DNA and protein approaches. Clinical prostate cancer. 2005 Review GET IT
Times cited: 8
Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clinical prostate cancer. 2005 Academic Article GET IT
Times cited: 32
Carbohydrate vaccines as immunotherapy for cancer. Immunology and cell biology. 2005 Review GET IT
Times cited: 157
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert opinion on therapeutic targets. 2005 Review GET IT
Times cited: 44
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005 Academic Article GET IT
Times cited: 74
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. Urology. 2005 Academic Article GET IT
Times cited: 7
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 105
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Applied immunohistochemistry & molecular morphology : AIMM. 2005 Academic Article GET IT
Times cited: 23
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer immunology, immunotherapy : CII. 2005 Academic Article GET IT
Times cited: 112
Cancer immunotherapeutics meeting. Expert opinion on investigational drugs. 2004 Conference Paper GET IT
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Academic Article GET IT
Times cited: 113
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 31
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 2004 GET IT
Times cited: 178
Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor. Cancer investigation. 2004 Letter GET IT
Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer. Urology. 2003 Review GET IT
Times cited: 7
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 166
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 34
DNA vaccines: an active immunization strategy for prostate cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 50
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Academic Article GET IT
Times cited: 63
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 15
Dendritic cell vaccines--hopeful or hopeless?. Cancer investigation. 2003 Editorial Article GET IT
Times cited: 6
Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety?. MedGenMed : Medscape general medicine. 2002 Academic Article GET IT
Times cited: 4
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 178
HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 125
Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Hematology/oncology clinics of North America. 2001 Review GET IT
Times cited: 18
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer. 2001 Academic Article GET IT
Times cited: 31
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 187
Chemotherapy for androgen- independent prostate cancer: myth or reality. Current oncology reports. 2000 Review GET IT
Times cited: 2
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 58
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center. Seminars in oncology. 1999 Review GET IT
Times cited: 37
Rising PSAs after primary therapy: active or passive intervention. Seminars in urologic oncology. 1999 Review GET IT
Times cited: 5
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proceedings of the National Academy of Sciences of the United States of America. 1999 Academic Article GET IT
Times cited: 251
A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle. Angewandte Chemie (International ed. in English). 1999 Academic Article GET IT
Detectable tumor cells in the blood and bone marrow: smoke or fire?. Cancer. 1998 Editorial Article GET IT
Times cited: 15
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 71
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 181
Immunological approaches for the treatment of prostate cancer. Seminars in urologic oncology. 1998 Review GET IT
Times cited: 30
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. The Urologic clinics of North America. 1997 Academic Article GET IT
Times cited: 62
Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. Seminars in oncology. 1996 Review GET IT
Times cited: 4
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Seminars in oncology. 1996 Review GET IT
Times cited: 21
The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro. Cancer. 1990 Academic Article GET IT
Times cited: 4
Immunotherapeutic approaches to the treatment of bone and soft tissue sarcomas. Seminars in oncology. 1989 Review GET IT
Times cited: 2
HLA-A2 in sarcomas: an immunobiologic perspective. Transplantation. 1987 Academic Article GET IT
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. Journal of immunology (Baltimore, Md. : 1950). 1986 Academic Article GET IT
Times cited: 74
Harnessing T-lymphocytes for human cancer immunotherapy. Cancer. 1985 Review GET IT
Times cited: 17
Epstein--Barr virus nuclear antigen in a non-Hodgkin's lymphoma. 1984 GET IT
Times cited: 2
Characterization of a monoclonal antibody that reacts with an activation antigen on human B cells: reactions on mitogen-stimulated blood lymphocytes and cells of normal lymph nodes. Blood. 1983 Academic Article GET IT
Times cited: 13
Analysis of cellular immune response to EBV by using cloned T cell lines. Journal of immunology (Baltimore, Md. : 1950). 1983 Academic Article GET IT
Times cited: 19
Antibodies to Epstein-Barr virus associated antigens in Pima Indians with and without rheumatoid arthritis. Rheumatology international. 1983 Academic Article GET IT
Times cited: 4
Lysis of autologous Epstein-Barr virus-infected B cells by cytotoxic T lymphocytes of rheumatoid arthritis patients. Clinical immunology and immunopathology. 1982 Academic Article GET IT
Times cited: 9
Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America. 1982 Academic Article GET IT
Times cited: 22
Different populations of rheumatoid factor idiotypes induced by two polyclonal B cell activators, pokeweed mitogen and Epstein--Barr virus. Clinical immunology and immunopathology. 1981 Academic Article GET IT
Times cited: 18
Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybrids. Journal of immunology (Baltimore, Md. : 1950). 1981 Academic Article GET IT
Times cited: 6
T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. Journal of immunology (Baltimore, Md. : 1950). 1981 Academic Article GET IT
Times cited: 35
Physiology and pathology of rheumatoid factors. Springer seminars in immunopathology. 1981 Academic Article GET IT
Times cited: 46
Toxic shock syndrome or Kawasaki disease. Annals of internal medicine. 1981 Letter GET IT
Times cited: 4
Tumor directed antibody and carcinoembryonic antigen in the glomeruli of a patient with gastric carcinoma. 1980 GET IT
Times cited: 29
Changes in the expression of two Epstein-Barr virus-associated antigens, EBNA and RANA, during the cell cycle of transformed human B lymphoblasts. International journal of cancer. 1980 Academic Article GET IT
Times cited: 6
Kawasaki disease in healthy young adult. 1980 GET IT
Evidence for the presence of receptors for C3 and IgG Fc on human synovial cells. Arthritis and rheumatism. 1980 Academic Article GET IT
Times cited: 46
Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America. 1979 Academic Article GET IT
Times cited: 78
Elution of tumor-directed antibody from kidneys of mammary tumor-bearing mice. Journal of the National Cancer Institute. 1977 Academic Article GET IT
Times cited: 5
An introduction to affinity chromatography. Advances in pathobiology. 1977 Academic Article GET IT

more ...

less ...

Background

education and training

M.D., Jefferson Medical College, Thomas Jefferson University 1990
Ph.D., Columbia University 1978
M.Phil., Columbia University 1977
M.A., Columbia University 1976
A.B., Barnard College - Columbia University 1974

Contact

full name

Susan Faith Slovin

VIVO Weill Cornell Medical College

Susan Faith Slovin Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name